• Cordomí A, Navarro G, Pérez L, Aymerich MS, Franco R. Structures for G-protein-coupled receptor tetramers in complex with G proteins. TIBS 2015 (en prensa)

  • Aymerich MS, Rojo Estefanía, Molina C, Celorrio M, Franco R. Neuroprotective effect of JZL184 in MPP+-treated SH-SY5Y cells through CB2 receptors. Mol. Neurobiol. 2015 (en prensa)

  • Fernández-Suárez D, Celorrio M, Riezu-Boj JI, Pacheco R, González H, Ugarte A, Hillard CJ, Oyarzabal J, Franco R, Aymerich MS. The monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial cell phenotype in the chronic MPTP mouse model. Neurobiol. Aging 2014 35(11):2603-16.

  • Ansorena E, Casales E, Garbayo E, Blanco-Prieto MJ, Smerdou C, Aymerich MS. A novel method for the production of human glial cell line-derived neurotrophic factor using a semliki forest virus expression system. Int J Pharmaceut. 2013 440(1):19-26.

  • Fernández-Suárez D, Celorrio M, Lanciego JL, Franco R, Aymerich MS.  Loss of parvalbumin-positive neurons from the globus pallidus in animal models of Parkinson disease. J Neuropathol Exp Neurol. 2012 71(11):973-82. 

  • Garbayo E, Ansorena E, Lanciego JL, Blanco-Prieto MJ, Aymerich MS. Long-term neuroprotection and neurorestoration by glial cell-derived neurotrophic factor microspheres for the treatment of Parkinson´s disease. Mov Dis 2011 26:1943-1947.

  • Navarro G, Moreno E, Aymerich M, Marcellino D, McCormick PJ, Mallol J, Cortes A, Casado V, Canela E, Ortiz J, Fuxe K, Lluis C, Ferré S, Franco R. Direct involvement of sigma-1 receptors in the dopamine D1 receptor-mediated effects of cocaine. PNAS 2010 107(43):18676-81.

"We try to identify new therapeutic targets with the aim of stopping, slowing down and/or reversing the neurodegenerative process that takes place in Parkinson's disease", Dra. Marisol Aymerich.

More information:


Cristina Canciani
Avda. Pío XII, 55
31008 Pamplona

(+34) 948 194 700 Ext. 2013